Wells Fargo raised the firm’s price target on Vertex Pharmaceuticals to $500 from $425 and keeps an Overweight rating on the shares. The firm notes Vertex setup into 2024 looks a lot better post chronic pain success. Wells has higher conviction into acute pain and next gen CF data next year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Stock (NASDAQ:VRTX) Hit a New 52-Week High Yesterday; Here’s Why
- Vertex Pharmaceuticals reports results from Phase 2 study of VX-548
- The biopharma stocks to own in 2024, according to Morgan Stanley
- Vertex Pharmaceuticals price target raised by $4 at Morgan Stanley, here’s why
- Vertex Pharmaceuticals’ positive results from CASGEVY trial highlighted at ASH